Dean Dauphinais did not buy his Klonopin from anyone. A doctor prescribed it, and he took it the way he was told. Years later, when he tried to come off, he wrote for Shatterproof that “I felt like I was dying. I had chills, my head hurt, and my body was shaking uncontrollably.” The way out took him years, shaving his dose down from five tablets a day to just over half of one. “I felt like Klonopin was holding me hostage,” he wrote.
Benzodiazepines hurt people twice: once when they’re handed out carelessly, and again when they’re taken away the same way.
That double harm is the through-line of this class right now. Benzodiazepines — Xanax, Klonopin, Valium, Ativan, and their cousins the “z-drugs” like Ambien — calm the brain by turning up its main braking system, a chemical messenger called GABA. Take them every day for weeks and the brain adjusts by easing off its own brakes. Remove the drug suddenly and the brakes are gone: anxiety, insomnia, tremor and, in the worst cases, seizures. If you have been through that, you already know it is not a character flaw. It is physiology.
Dependence is not addiction, and the guideline finally says so
For years, people in Dauphinais’s position were filed under the wrong heading. The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering — written by the American Society of Addiction Medicine with nine other medical societies and funded by the FDA — draws the line in plain language: “physical dependence is an expected outcome associated with BZD use and is distinct from BZD use disorder.” Put simply: your body getting used to a medicine is not the same as the medicine taking over your life. ASAM’s own summary puts numbers on it: “Nearly all patients who take BZD regularly for more than a month will develop physical dependence,” but “only 1.5% will develop a BZD use disorder.”
The guideline’s taper math is slow on purpose. Start with cuts of 5 to 10% every two to four weeks, and “the taper should typically not exceed 25% every 2 weeks.” For someone on a high dose for more than a year, the pace drops to 5 to 10% every six to eight weeks. That is a taper measured in seasons, not days. The same document warns that “well-intentioned guidelines can be mis-applied and lead to patient harm” — a sentence written by people who watched exactly that happen with opioids.
The harm on the far end of a bad taper is not hypothetical. A 2023 PLOS ONE survey led by Alexis Ritvo collected reports from 1,207 people with what the authors named benzodiazepine-induced neurological dysfunction, or BIND — symptoms that linger long after the drug is gone. Most respondents said their symptoms lasted months or more than a year; more than half reported suicidal thoughts or attempts, and nearly half lost work. The limits matter and you should know them: respondents were recruited from online support groups, there was no comparison group, and the authors themselves say not everyone who takes benzos develops BIND. But one of the co-authors, cardiologist Christy Huff, said it straight: “Patients have been reporting long-term effects from benzodiazepines for over 60 years. I am one of those patients.”
We have run this exact cycle before
Benzodiazepines arrived as the safe alternative. Librium came to market around 1960 and Valium in 1963; by 1966 the Rolling Stones were singing about “Mother’s Little Helper.” Valium was America’s best-selling drug from 1968 to 1982, peaking at roughly two billion tablets in 1978. Then the backlash came, and it came the way backlashes do — as a blanket rule. In February 1988 the British government told the House of Lords that every doctor in the country had been mailed advice to prescribe benzodiazepines for “two to four weeks only” because “of the danger of patients becoming dependent.” The advice was right for new patients. For the people already on them for a decade, there was very little: a psychopharmacologist named Heather Ashton ran a benzodiazepine withdrawal clinic in Newcastle from 1982 to 1994 and wrote the slow-taper manual that patients still pass hand to hand. We did it again with opioids after 2016 — careless prescribing, then careless cutting off, with patients in the middle both times.
Then the backlash came, and it came the way backlashes do — as a blanket rule.
The prescriptions are falling. The supply isn’t.
The handing-out half of the story is improving. A Rutgers team analyzing more than 1.1 billion fills, published in the American Journal of Psychiatry, found benzodiazepine dispensing fell 26.7% from 2013 to 2024, with the average dose per prescription down 18.3% and the sharpest drop among adults 18 to 29. “Prescribing practices may have become more cautious or selective,” lead author Naomi Cruz said in the university’s release. Good. But a quieter prescription market has a shadow, and it is showing up in the drug supply.
On November 2, Baltimore’s health department warned that benzodiazepine-positive drug samples in Maryland more than doubled — 31 from April to July 2026, against 14 a year earlier — including bromazolam and ethylbromazolam, designer benzos sold by no pharmacy anywhere. On November 19, Toronto’s drug checking service reported that 96% of its “fentanyl” samples were cut with at least one non-opioid drug, and more than a quarter carried a high-potency opioid, a veterinary tranquilizer and a benzo together. “What keeps me up at night is the fact that we do not control these markets,” epidemiologist Dan Werb said.
The people buying that supply know what it feels like from inside. A new qualitative study in Addiction by Vojt and colleagues, built on interviews with 48 people in the UK who use benzodiazepines or z-drugs alongside opioids, came back with themes in the participants’ own words: “consumption roulette,” “can I keep myself safe?” and “they don’t care about us.” Those three phrases are the whole trend line. A pill you didn’t choose, a dose you can’t know, and a system you’ve stopped expecting anything from. We wrote last week about what medetomidine withdrawal feels like; sedatives stacked on fentanyl are the same story with a different molecule.
Here is the part that matters tonight. Naloxone reverses opioids, not benzodiazepines — Baltimore’s advisory says it “will NOT counteract a benzodiazepine’s sedative properties.” It is still worth giving, because almost every one of these overdoses includes an opioid. Then call 911 and give rescue breaths, because the benzo half of the overdose slows breathing and only air fixes that. And if you are on a prescription and want off, do not stop on your own. The guideline is on your side; take it to your prescriber and ask for the slow version.
For clinicians, the do-this-week move is simple. Before any benzo dose change, ask and chart one question: is this physical dependence or a use disorder? They get different plans. Then hold the taper to the guideline’s ceiling — no more than 25% every two weeks, slower for long-term patients — and schedule the follow-up before the first cut, not after the first crisis. If your patients also use opioids, put naloxone and a rescue-breathing explanation in their hands at the same visit.
The FDA’s 2020 boxed warning already told prescribers that stopping these drugs “abruptly or reducing the dosage too quickly can result in withdrawal reactions.” Six years later, Dauphinais’s line is still the best summary of what happens when nobody listens: a medicine that held him hostage, and a release that had to be negotiated one sliver at a time. He made it out. The point of getting this right is that the next person shouldn’t need years to do it.
More on this class lives in our depressants hub and the Science & Medicine section.
Sources Cited
- 01.A
- 02.AJoint Clinical Practice Guideline on Benzodiazepine TaperingJournal of General Internal Medicine
- 03.B
- 04.ANational Trends in Benzodiazepine DispensingAmerican Journal of Psychiatry
- 05.BBenzodiazepine prescriptions fell sharply over the past decadeMedical Xpress / Rutgers
- 06.A
- 07.B
- 08.BMy Klonopin NightmareShatterproof
- 09.APublic Health Advisory: Ongoing Threat of Benzodiazepines in Illicit Drug SupplyBaltimore City Health Department
- 10.BNew designer drug found in Toronto fentanyl supplyCP24 / The Canadian Press
- 11.A
- 12.ABenzodiazepines: Prescribing — House of Lords debate, 26 February 1988UK Parliament (Hansard)
- 13.B
- 14.BProfessor C Heather Ashton — curriculum vitaebenzo.org.uk
Filed Under
sciencesocial-culturaltrendsBenzodiazepinesDesigner BenzodiazepinesZ-DrugsPolysubstanceFDAPeer-Reviewed ResearchGovernment DataRelapse Prevention
Keep up with the reporting.
One email each morning with the stories that put days like this in context.